Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | MDM4 | O15151 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | FABP7 | O15540 | 1/20 | 0.37 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10018302 | 0.84 | KMT2A (0.47) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL10018272 | 0.84 | KMT2A (0.41) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL30421778 | 0.82 | KMT2A (0.57) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL30896041 | 0.82 | KMT2A (0.57) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL14957061 | 0.82 | KMT2A (0.57) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL15434690 | 0.81 | KMT2A (0.53) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL24769841 | 0.81 | KMT2A (0.57) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL15434624 | 0.79 | KMT2A (0.51) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL29523575 | 0.78 | KMT2A (0.55) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL22188058 | 0.78 | KMT2A (0.55) | KMT2AEPHX2CASP3MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142763-A1 | NUCLEIC ACID DELIVERY COMPOSITIONS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142763-A1 | NUCLEIC ACID DELIVERY COMPOSITIONS AND METHODS OF USE THEREOF | NSUN3, NSUN2, DIS3 | KMT2A 2214/4885EPHX2 3536/4885CASP3 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.